-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Adagio Therapeutics announced today that it has completed a $336 million Series C financing led by RA Capital Management.
ADG20 may affect virus replication and related diseases through a variety of mechanisms of action, including directly blocking virus entry into host cells (neutralization) and mediated by Fc receptors (Fc receptors are receptors that bind to the Fc part of immunoglobulin) The immune effector activity eliminates infected host cells.
Adagio has initiated a phase 1 clinical study in healthy volunteers and is conducting a pivotal phase 1/2/3 clinical trial in high-risk patients with mild or moderate COVID-19.
Reference materials:
Reference materials:[1] Adagio Therapeutics Announces $336 Million Series CFinancing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19.
[1] Adagio Therapeutics Announces $336 Million Series CFinancing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19.
[2] Adagio Therapeutics Announces Dosing of First Patient inPhase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19.
[3] Evaluation of ADG20 for the Treatment of Mild orModerate COVID-19-Full Text View-ClinicalTrials.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number